Biotechnology Today
more-
FDA expands label of 23andMe genetic report predicting response to popular cholesterol drug
In recent years, 23andMe has repositioned itself as a genetic testing company that does more…
No remedy for DiaMedica as FDA maintains hold on stroke trial over IV concerns
‘We can turn this ship around’: FDA, Edwards on how devicemakers can better serve female patients
GSK dumps major pipeline prospect otilimab on lackluster phase 3 data in rheumatoid arthritis
Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval
Markets
more-
Weekly Market Review – November 26, 2022
Stock Markets The holiday-truncated trading week produced gains in the major stock benchmarks. The Dow…
Bio Space
more
Merck & Co. ditches oncolytic virus Cavatak 4 years after buying Viralytics
Merck & Co. is bidding adieu to the oncolytic virus…
Bluebird spinout 2seventy bio, JW Therapeutics ink $3M deal for solid tumor cell therapy program
Bluebird spinout 2seventy bio and China-based CAR-T company JW Therapeutics…
Bristol Myers keeps Obsidian cell therapy pact rocking with multiyear extension
Bristol Myers Squibb has inked a multiyear extension to its…
Global News
more
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
Facebook video calls soar 1000% during Italy’s lockdown
Facebook has seen usage across its platforms surge in countries…
WeWork board’s special committee is demanding that SoftBank follow through with investment
Five months after SoftBank agreed to a massive bailout of…
FDA expands label of 23andMe genetic report predicting response to popular cholesterol drug
No remedy for DiaMedica as FDA maintains hold on stroke trial over IV concerns
‘We can turn this ship around’: FDA, Edwards on how devicemakers can better serve female patients
GSK dumps major pipeline prospect otilimab on lackluster phase 3 data in rheumatoid arthritis
Merck & Co. ditches oncolytic virus Cavatak 4 years after buying Viralytics
Bluebird spinout 2seventy bio, JW Therapeutics ink $3M deal for solid tumor cell therapy program
Bristol Myers keeps Obsidian cell therapy pact rocking with multiyear extension
The Time 100: LA-based VC firm closes $100M fund to spice up biotech with Silicon Valley star power
Seres one step closer to bringing first oral microbiome therapy to market as FDA mulls approval
Clario highlights 3 areas where AI can support patients in decentralized trials